

Christopher B Benton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8926173/publications.pdf>

Version: 2024-02-01

72
papers

1,541
citations

393982

19
h-index

315357

38
g-index

72
all docs

72
docs citations

72
times ranked

2531
citing authors

#	ARTICLE	IF	CITATIONS
1	Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer. <i>Acta Haematologica</i> , 2021, 144, 585-590.	0.7	3
2	Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1265-1265.	0.6	1
3	First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. <i>Frontiers in Oncology</i> , 2020, 10, 1538.	1.3	6
4	Thirty-three years later: Two distinct cases of acute lymphoblastic leukemia in one patient. <i>American Journal of Hematology</i> , 2020, 95, 1117-1120.	2.0	0
5	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	2.5	86
6	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e480-e488.	2.2	103
7	Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2019, 142, 176-184.	0.7	2
8	<i>DDX41</i> mutations in myeloid neoplasms are associated with male gender, <i>TP53</i> mutations and high-risk disease. <i>American Journal of Hematology</i> , 2019, 94, 757-766.	2.0	86
9	Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1855-1866.	2.0	21
10	Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Hematological Oncology</i> , 2019, 37, 96-102.	0.8	8
11	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	2.2	84
12	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	0.6	15
13	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 645-645.	0.6	9
14	Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. <i>Blood</i> , 2019, 134, 738-738.	0.6	3
15	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2019, 134, 2642-2642.	0.6	2
16	Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1719-1719.	0.6	0
17	Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 1711-1711.	0.6	0
18	Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2717-2717.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. <i>Cancer</i> , 2018, 124, 2704-2713.	2.0	39
20	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2238-2241.	0.6	20
21	Erythroleukemia-historical perspectives and recent advances in diagnosis and management. <i>Blood Reviews</i> , 2018, 32, 96-105.	2.8	35
22	Clinical experience with the BCL2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 401-407.	2.0	336
23	Early detection of transformation to BPDCN in a patient with MDS. <i>Experimental Hematology and Oncology</i> , 2018, 7, 26.	2.0	13
24	Prognosis of patients with intermediate risk IPSS myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS. <i>American Journal of Hematology</i> , 2018, 93, 1245-1253.	2.0	34
25	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	2.2	66
26	Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. <i>Blood</i> , 2018, 132, 2674-2674.	0.6	1
27	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 286-286.	0.6	19
28	Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. <i>Blood</i> , 2018, 132, 84-84.	0.6	6
29	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 905-905.	0.6	21
30	Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. <i>Blood</i> , 2018, 132, 4367-4367.	0.6	2
31	Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 232-232.	0.6	11
32	Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. <i>Blood</i> , 2018, 132, 4057-4057.	0.6	10
33	Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 4017-4017.	0.6	5
34	Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≥ 65 yrs) with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 4039-4039.	0.6	1
35	Diverse Landscape of TET2 Variants in MDS and AML. <i>Blood</i> , 2018, 132, 1479-1479.	0.6	0
36	Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. <i>Blood</i> , 2018, 132, 1514-1514.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 2722-2722.	0.6	2
38	Distinct Gene Expression Patterns of Minimal Residual Disease (MRD) Cells in High-Risk AML Patients Identified By RNA-Sequencing. <i>Blood</i> , 2018, 132, 2757-2757.	0.6	0
39	Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2791-2791.	0.6	0
40	Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1820-1820.	0.6	0
41	Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. <i>American Journal of Hematology</i> , 2017, 92, 119-120.	2.0	2
42	More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. <i>Blood</i> , 2017, 129, 2584-2587.	0.6	51
43	FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia. <i>Blood</i> , 2017, 129, 1958-1968.	0.6	16
44	Increased peripheral leukemia blasts leading to false-positive blood culture. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 64, 8-9.	0.6	2
45	Poor outcomes associated with +der(22)t(9;22) and $\hat{\sim}9/9p$ in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	2.0	41
46	Targeting Histone Acetylation. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 286-291.	1.0	35
47	JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. <i>Leukemia Research</i> , 2017, 63, 53-55.	0.4	0
48	Targeting acute myeloid leukemia with TP53-independent vosaroxin. <i>Future Oncology</i> , 2017, 13, 125-133.	1.1	5
49	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323.	2.5	83
50	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 815-815.	0.6	11
51	A mind map for managing minimal residual disease in acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 859-867.	0.3	4
52	Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. <i>Cancer</i> , 2016, 122, 2857-2866.	2.0	88
53	Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. <i>American Journal of Hematology</i> , 2016, 91, 1221-1226.	2.0	12
54	Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. <i>Blood</i> , 2016, 128, 1612-1612.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. <i>Blood</i> , 2016, 128, 2744-2744.	0.6	17
56	Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 2817-2817.	0.6	2
57	Pure Erythroid Leukemia Is Characterized By TP53 mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. <i>Blood</i> , 2016, 128, 2852-2852.	0.6	2
58	Targeting Aggregation of Wild-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML. <i>Blood</i> , 2016, 128, 3944-3944.	0.6	2
59	Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. <i>Blood</i> , 2016, 128, 3975-3975.	0.6	2
60	Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. <i>Blood</i> , 2016, 128, 597-597.	0.6	0
61	Optimized Voronoi compartment determination using machine-learning to identify prognostic groups of patients based on cellular behavior in treated AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S22.	0.2	1
62	Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 939-946.	1.3	32
63	Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. <i>Leukemia Research</i> , 2015, 39, 419-423.	0.4	9
64	Chronic myelomonocytic leukemia: Forefront of the field in 2015. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 222-242.	2.0	22
65	Lineage-negative, CD34-negative, CD45-negative (Lin-CD34-CD45-) leukemia cells from primary adult AML samples have distinct stem cell-like properties. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S21-S22.	0.2	1
66	Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS. <i>Blood</i> , 2015, 126, 1663-1663.	0.6	5
67	Safety and clinical activity of 5-azadeoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 356-365.	1.2	37
68	Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. <i>Leukemia and Lymphoma</i> , 2014, 55, 1431-1434.	0.6	4
69	Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo. <i>Blood</i> , 2013, 122, 3685-3685.	0.6	2
70	Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status. <i>Blood</i> , 2013, 122, 2584-2584.	0.6	0
71	Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse. <i>Blood</i> , 2012, 120, 360-360.	0.6	0
72	Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy. <i>Blood</i> , 2012, 120, 1417-1417.	0.6	0